10 Biotechnology Stocks to Sell Now

by Portfolio Grader | September 4, 2013 10:45 am

The ratings of 10 Biotechnology stocks are down this week, according to the Portfolio Grader[1] database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK[2]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Merrimack Pharmaceuticals, Inc. is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. In Portfolio Grader’s specific subcategories of Earnings Revisions and Cash Flow, MACK also gets F’s. The stock price has fallen 29.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of Sept. 4, 2013, 11.7% of outstanding Merrimack Pharmaceuticals, Inc. shares were held short. For a full analysis of MACK stock, visit Portfolio Grader[3].

Genomic Health, Inc. (NASDAQ:GHDX[4]) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock price has fallen 8.3% over the past month. The stock has a trailing PE Ratio of 799.00. For more information, get Portfolio Grader’s complete analysis of GHDX stock[5].

This is a rough week for Acorda Therapeutics, Inc. (NASDAQ:ACOR[6]). The company’s rating falls to D from the previous week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 7.1% over the past month. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock[7].

This week, Amarin Corporation Plc Sponsored ADR (NASDAQ:AMRN[8]) drops from a C to a D rating. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of Sept. 4, 2013, 13.2% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader[9].

This week, Durata Therapeutics, Inc.’s (NASDAQ:DRTX[10]) rating worsens to a D from the company’s C rating a week ago. Durata Therapeutics is a pharmaceutical company that focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The stock gets F’s in Earnings Revisions, Equity, and Cash Flow. To get an in-depth look at DRTX, get Portfolio Grader’s complete analysis of DRTX stock[11].

Exelixis, Inc. (NASDAQ:EXEL[12]) experiences a ratings drop this week, going from last week’s D to an F. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Sept. 4, 2013, 21.9% of outstanding Exelixis, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock[13].

Trius Therapeutics, Inc.’s (NASDAQ:TSRX[14]) rating weakens this week, dropping to a D versus last week’s C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock[15].

The rating of Cell Therapeutics, Inc. (NASDAQ:CTIC[16]) declines this week from a D to an F. Cell Therapeutics develops, acquires, and sells new treatments for cancer. The stock gets F’s in Equity and Cash Flow. For a full analysis of CTIC stock, visit Portfolio Grader[17].

The rating of Discovery Laboratories (NASDAQ:DSCO[18]) slips from a C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of DSCO stock[19].

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN[20]) earns a D this week, moving down from last week’s grade of C. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 7.1% over the past month. As of Sept. 4, 2013, 15.1% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock[21].

Louis Navellier’s proprietary Portfolio Grader[22] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[23].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. MACK: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MACK
  3. For a full analysis of MACK stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MACK
  4. GHDX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GHDX
  5. For more information, get Portfolio Grader’s complete analysis of GHDX stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GHDX
  6. ACOR: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACOR
  7. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACOR
  8. AMRN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AMRN
  9. For a full analysis of AMRN stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AMRN
  10. DRTX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DRTX
  11. To get an in-depth look at DRTX, get Portfolio Grader’s complete analysis of DRTX stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DRTX
  12. EXEL: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=EXEL
  13. For more information, get Portfolio Grader’s complete analysis of EXEL stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=EXEL
  14. TSRX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TSRX
  15. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TSRX
  16. CTIC: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CTIC
  17. For a full analysis of CTIC stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CTIC
  18. DSCO: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  19. For more information, get Portfolio Grader’s complete analysis of DSCO stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  20. ACHN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  21. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  22. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  23. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2013/09/10-biotechnology-stocks-to-sell-now-mack-ghdx-acor/
Short URL: http://invstplc.com/1nw58HR